An Ongoing Phase 1–2a Study of EO1001, an Oral Brain-Penetrant Pan-ErbB Inhibitor,in Patients with Advanced ErbB-Driven Solid Tumors Including CNS Disease
Sophia Frentzas¹, Malaka Ameratunga²˒
³, Amy L. Body¹, Daphne Day¹, Richard Kelly², Penny Macquire¹, Yasmin Malik², Lauren Murphy¹, Jeremy Neeman¹, Siang Tan¹, Jeffrey A. Bacha⁵, Sarath Kanekal⁵, Mike T. Li⁵, Ian Nisbet⁴, Neil Sankar⁵, Kathy Skoff⁴, Dennis M. Brown⁵
¹Monash Health, Melbourne, Australia; ²The Alfred, Melbourne, Australia; ³School of Translational Medicine, Monash University,
Background
Central nervous system (CNS) metastases and primary brain tumors remain a major cause of morbidity and mortality in patients with ErbB-driven malignancies, particularly as improved systemic therapies prolong survival. Aberrations in the ErbB family of receptor tyrosine kinases—including EGFR, HER2, and HER4—are frequently associated with CNS progression, therapeutic resistance, and poor outcomes across multiple tumor types. In glioblastoma and other CNS malignancies, specific EGFR extracellular domain (ECD) alterations, including EGFRvIII and recurrent ECD missense variants, have been previously reported to promote ligand-independent signaling, invasive tumor biology, and resistance to currently available EGFR-targeted therapies.
EO1001 is a novel, oral, irreversible pan-ErbB inhibitor designed to achieve sustained CNS exposure and broad ErbB pathway inhibition, demonstrating potent activity in intracranial xenograft models of EGFR-altered primary brain tumors – including EGFR+ (GBM12) and EGFRvIII-amplified/high-expressing (GBM39, U87) glioblastoma models – as well as across distinct EGFR extracellular domain (ECD) mutation classes, with greater or more sustained activity relative to FDA-approved ErbB inhibitors in preclinical studies.
About Edison Oncology Holding Corp.
Edison Oncology Holding Corp. is a clinical-stage biopharmaceutical company developing a pipeline of first-in-class, small-molecule, biomarker-driven therapies designed to overcome key resistance mechanisms and address critical unmet needs in aggressive and underserved cancers. Leveraging existing clinical data and a modern understanding of cancer biology, Edison Oncology focuses on genetically defined cancers, advancing its programs through a capital-efficient combination of internal development and strategic partnerships while retaining meaningful development and commercial rights. To learn more, please visit https://www.edisononcology.com/ and follow us for updates on LinkedIn.
Contact
Hayden IR
Brett Maas
(646) 536-7331
brett@haydenir.com
or
James Carbonara
(646)-755-7412
james@haydenir.com